Kiora Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.kiorapharma.com
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06825702
- Locations
- 🇦🇺
Sydney Eye Hospital, Sydney, New South Wales, Australia
🇦🇺Coastal Eye Centre, Birtinya, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa
Phase 2
Not yet recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06628947
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05629364
- Locations
- 🇦🇺
Ophthalmic Trials Australia, Teneriffe, Queensland, Australia
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Phase 2
Completed
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Drug: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05436288
- Locations
- 🇲🇽
Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Chimalpopoca 14 Colonia Obrera, Mexico
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia (ABACUS)
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Kiora Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05282953
- Locations
- 🇦🇺
Royal Adeliade Hospital, Adelaide, South Australia, Australia
🇦🇺Harley Eye Clinic, North Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath